Gyre Therapeutics price to free cash flow GYRE

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 211×; Aug 2026
Peer median: 7.5×

Gyre Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2026, at 211×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	211×	182×	275×
2025	241×	29.0×	266×
2024	36.1×	28.0×	38.1×

Against its peers

Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.

Company	Price to free cash flow
GYREGyre Therapeutics	n/m
CRMDCorMedix	2.4×
ZVRAZevra Therapeutics	17.9×
IRWDIronwood Pharmaceuticals	n/m
COLLCollegium Pharmaceutical	2.3×
PBYIPuma Biotechnology	13.8×
ABUSArbutus Biopharma	n/m
ARVNArvinas	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
PCRXPacira BioSciences	8.1×
Peer median	7.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Gyre Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.